Topex has sold its skin cancer business operations to Sensus Healthcare for its low energy SRT 100 superficial radiotherapy treatment system, which provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers.
Since Topex has received US Food and Drug Administration approval in 2007 many systems have been operating worldwide at hospital radiation oncology centers, dermatology and veterinary oncology practices for the treatment of skin cancer.
The low energy superficial radiotherapy system provides treatment for skin cancers especially primary lesions requiring difficult or extensive surgery with sensitive structures in the head and neck regions, the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear that would otherwise lead to a less than desirable cosmetic outcome.
The treatment procedure does not require the use of anesthetics and eliminates the need for skin grafting.
Topex founder and CEO Anthony Pellegrino said that Sensus Healthcare brings together a skilled team of technical sales and marketing professionals for expanding superficial radiotherapy clinical use and business development in the global marketplace.
Sensus Healthcare CEO Joe Sardano said that superficial radiotherapy provides a non invasive choice to treat skin cancer with appropriate dose levels and proven clinical high cure rates and Sensus is privileged to offer this technology as well as other products and services to this market segment.